Regression of vasoproliferative tumor with systemic infliximab

dc.contributor.authorJapiassu, Ricardo Miguel
dc.contributor.authorBrasil, Oswaldo Ferreira Moura [UNIFESP]
dc.contributor.authorCunha, Anibal Luis Gomes
dc.contributor.authorSouza, Eduardo Cunha de [UNIFESP]
dc.contributor.institutionUniversidade do Estado do Rio de Janeiro (UERJ)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.abstractThe anti-tumor necrosis factor (TNF) monoclonal antibody infliximab inhibits the pleiotropic actions of TNF and is widely used for the treatment of inflammatory diseases, such as uveitis. A pathogenetic role of TNF in ocular inflammatory conditions has recently emerged. The authors describe a patient with collagen mixed disease who had decreased vision in the left eye. Fundus examination disclosed bilateral peripheral vasoproliferative tumors and macular edema in the left eye. The patient underwent treatment with infliximab intravenously for his systemic condition. Regression of the vasoproliferative tumors in both eyes and improvement of macular edema in the left eye was observed. Although the data are limited, anti-TNF antibodies such as infliximab may be useful in the treatment of retinal vascular tumors.en
dc.description.affiliationUniv Estado Rio de Janeiro, Pedro Ernesto Univ Hosp, BR-20550011 Rio De Janeiro, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Vis Inst, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.identifier.citationOphthalmic Surgery Lasers & Imaging. Thorofare: Slack Inc, v. 39, n. 4, p. 348-349, 2008.
dc.publisherSlack Inc
dc.relation.ispartofOphthalmic Surgery Lasers & Imaging
dc.rightsAcesso restrito
dc.titleRegression of vasoproliferative tumor with systemic infliximaben